Co-delivery of Siape1 and Melatonin by 125 I-loaded PSMA-targeted Nanoparticles for the Treatment of Prostate Cancer.

Ying LiuLin HaoYang DongBing-Zheng DongXin-Lei WangXing LiuZheng-Xiang HuGao-Chuan FangGuang-Yue WangJia-Xin QinZhen-Duo ShiKun Pang

Published in: Recent patents on anti-cancer drug discovery (2024)

The PSMA-targeted nanocarrier encapsulating siAPE1 and melatonin is a promising therapeutic strategy for PCa and can provide a theoretical basis for patent applications.

Keyphrases

prostate cancer
cancer therapy
pet ct
drug delivery
pet imaging
radical prostatectomy
combination therapy